Alnylam submits regulatory applications to the u.s. food and drug administration and european medicines agency to support label expansion for oxlumo® for the treatment of advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today the submission of a supplemental new drug application (snda) to the u.s. food and drug administration (fda) and type ii filing variation to the european medicines agency (ema) for lumasiran, an investigational rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – for the reduction of plasma oxalate in the treatment
ALNY Ratings Summary
ALNY Quant Ranking